AMRX RSI Chart
Last 7 days
2.4%
Last 30 days
24.9%
Last 90 days
15.6%
Trailing 12 Months
203.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 2.5B | 0 | 0 | 0 |
2023 | 2.3B | 2.3B | 2.4B | 2.4B |
2022 | 2.1B | 2.1B | 2.1B | 2.2B |
2021 | 2.0B | 2.1B | 2.1B | 2.1B |
2020 | 1.7B | 1.7B | 1.9B | 2.0B |
2019 | 1.8B | 1.8B | 1.7B | 1.6B |
2018 | 1.1B | 1.2B | 1.5B | 1.7B |
2017 | 1.0B | 1.0B | 1.0B | 1.0B |
2016 | 0 | 0 | 0 | 1.0B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 12, 2024 | konidaris tasos | sold (taxes) | -163,495 | 5.31 | -30,790 | executive vice president & cfo |
Mar 12, 2024 | konidaris tasos | acquired | - | - | 87,720 | executive vice president & cfo |
Mar 03, 2024 | shah nikita | sold (taxes) | -225,008 | 5.47 | -41,135 | executive vice president |
Mar 03, 2024 | konidaris tasos | sold (taxes) | -197,046 | 5.47 | -36,023 | executive vice president & cfo |
Mar 03, 2024 | boyer andrew s | sold (taxes) | -243,754 | 5.47 | -44,562 | executive vice president |
Mar 03, 2024 | boyer andrew s | acquired | - | - | 88,945 | executive vice president |
Mar 03, 2024 | daly jason b. | acquired | - | - | 60,871 | svp, chief legal officer |
Mar 03, 2024 | shah nikita | acquired | - | - | 82,103 | executive vice president |
Mar 03, 2024 | daly jason b. | sold (taxes) | -98,624 | 5.47 | -18,030 | svp, chief legal officer |
Mar 03, 2024 | konidaris tasos | acquired | - | - | 102,629 | executive vice president & cfo |
Which funds bought or sold AMRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 5.44 | 37,143 | 742,374 | -% |
May 16, 2024 | COMERICA BANK | reduced | -27.91 | -2,134 | 5,480 | -% |
May 16, 2024 | Virtus Investment Advisers, Inc. | reduced | -42.2 | -153,309 | 209,131 | 0.15% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 15.52 | 104,916 | 789,260 | -% |
May 15, 2024 | Aquatic Capital Management LLC | new | - | 435,714 | 435,714 | 0.01% |
May 15, 2024 | MORGAN STANLEY | added | 116 | 3,108,410 | 5,793,130 | -% |
May 15, 2024 | JACOBS LEVY EQUITY MANAGEMENT, INC | reduced | -13.74 | -337,211 | 2,092,200 | 0.01% |
May 15, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 6.76 | 30,000 | 493,000 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 21.59 | 236,387 | 1,341,290 | -% |
May 15, 2024 | Centiva Capital, LP | new | - | 349,577 | 349,577 | 0.01% |
Unveiling Amneal Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Amneal Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Amneal Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 6.8% | 659 | 617 | 620 | 599 | 558 | 610 | 546 | 559 | 498 | 537 | 529 | 535 | 493 | 510 | 519 | 465 | 499 | 397 | 378 | 405 | 446 |
Gross Profit | 25.4% | 238 | 190 | 233 | 220 | 178 | 215 | 194 | 201 | 175 | 166 | 199 | 212 | 192 | 167 | 134 | 144 | 183 | 110 | 54.00 | 105 | 83.00 |
S&GA Expenses | 3.3% | 113 | 109 | 113 | 106 | 102 | 102 | 100 | 99.00 | 99.00 | 97.00 | 91.00 | 86.00 | 91.00 | 85.00 | 83.00 | 81.00 | 78.00 | 74.00 | 64.00 | 67.00 | 84.00 |
R&D Expenses | -14.7% | 39.00 | 46.00 | 41.00 | 38.00 | 39.00 | 42.00 | 50.00 | 51.00 | 53.00 | 52.00 | 49.00 | 53.00 | 48.00 | 53.00 | 45.00 | 46.00 | 36.00 | 48.00 | 38.00 | 48.00 | 54.00 |
EBITDA Margin | -30.9% | 0.04* | 0.06* | 0.09* | 0.08* | -0.04* | -0.05* | -0.06* | -0.07* | 0.06* | 0.07* | 0.08* | 0.07* | 0.05* | 0.05* | 0.03* | 0.06* | 0.05* | -0.04* | -0.01* | -0.01* | -0.13* |
Interest Expenses | 14.8% | 65.00 | 56.00 | 48.00 | 48.00 | 41.00 | 51.00 | 35.00 | 30.00 | 27.00 | 30.00 | 30.00 | 32.00 | 30.00 | 31.00 | 31.00 | 33.00 | 35.00 | 37.00 | 41.00 | 41.00 | 40.00 |
Income Taxes | -37.8% | 6.00 | 10.00 | -2.08 | - | 1.00 | -1.80 | 5.00 | 7.00 | -3.50 | 4.00 | 4.00 | 3.00 | 0.00 | 2.00 | 0.00 | 2.00 | -108 | 7.00 | 390 | -5.70 | -8.43 |
Earnings Before Taxes | 9.5% | -75.52 | -83.46 | 23.00 | 30.00 | -9.43 | -7.65 | 2.00 | -232 | -9.92 | -16.32 | -2.04 | 35.00 | 15.00 | -5.48 | -21.89 | -21.76 | 13.00 | -57.11 | 26.00 | -56.23 | -133 |
EBT Margin | -153.4% | -0.04* | -0.02* | 0.01* | 0.01* | -0.11* | -0.11* | -0.12* | -0.12* | 0.00* | 0.01* | 0.02* | 0.01* | -0.02* | -0.02* | -0.05* | -0.02* | -0.04* | -0.14* | -0.10* | -0.10* | -0.21* |
Net Income | 9.6% | -91.64 | -101 | 16.00 | 22.00 | -15.63 | -12.03 | -7.61 | -242 | -8.82 | -21.80 | -7.78 | 30.00 | 13.00 | -6.83 | -21.64 | -24.16 | 120 | -64.90 | -265 | -16.90 | -47.88 |
Net Income Margin | -87.9% | -0.06* | -0.03* | 0.00* | -0.01* | -0.12* | -0.12* | -0.13* | -0.13* | 0.00* | 0.01* | 0.01* | 0.01* | -0.02* | 0.03* | 0.01* | -0.13* | -0.13* | -0.24* | -0.20* | -0.04* | -0.16* |
Free Cashflow | -110.8% | -13.61 | 126 | 70.00 | -23.35 | 130 | -34.76 | 74.00 | -130 | 110 | 46.00 | 72.00 | -59.74 | 136 | 76.00 | 34.00 | 171 | 42.00 | -55.41 | 127 | 9.00 | -126 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -0.5% | 3,456 | 3,473 | 3,687 | 3,701 | 3,627 | 3,799 | 3,874 | 4,041 | 3,889 | 3,940 | 3,974 | 4,023 | 3,960 | 4,006 | 4,038 | 4,057 | 4,391 | 3,666 | 3,704 | 4,262 | 4,385 |
Current Assets | 0.2% | 1,380 | 1,378 | 1,456 | 1,422 | 1,307 | 1,412 | 1,420 | 1,554 | 1,390 | 1,520 | 1,570 | 1,563 | 1,560 | 1,552 | 1,544 | 1,481 | 1,774 | 1,210 | 1,206 | 1,186 | 1,268 |
Cash Equivalents | -43.6% | 52.00 | 92.00 | 87.00 | 109 | 145 | 26.00 | 87.00 | 92.00 | 210 | 248 | 303 | 278 | 452 | 347 | 281 | 266 | 405 | 153 | 213 | 55.00 | 64.00 |
Inventory | -1.8% | 571 | 581 | 576 | 551 | 529 | 531 | 544 | 533 | 512 | 489 | 520 | 523 | 497 | 491 | 476 | 444 | 438 | 381 | 402 | 415 | 448 |
Net PPE | -1.7% | 440 | 448 | 452 | 459 | 463 | 470 | 470 | 484 | 501 | 514 | 460 | 468 | 471 | 478 | 462 | 461 | 468 | 478 | 491 | 508 | 514 |
Goodwill | 0.0% | 599 | 599 | 599 | 599 | 599 | 599 | 600 | 601 | 603 | 593 | 566 | 549 | 44.00 | 523 | 523 | 527 | 515 | 420 | 420 | 420 | 422 |
Current Liabilities | -1.4% | 834 | 847 | 761 | 777 | 704 | 753 | 818 | 993 | 602 | 677 | 667 | 673 | 637 | 677 | 668 | 655 | 965 | 550 | 535 | 546 | 600 |
Long Term Debt | -0.3% | 2,378 | 2,386 | 2,542 | 2,549 | 2,562 | 2,592 | 2,607 | 2,622 | 2,673 | 2,680 | 2,688 | 2,720 | 2,728 | 2,735 | 2,757 | 2,765 | 2,772 | 2,609 | 2,614 | 2,620 | 2,625 |
LT Debt, Current | -1.4% | 34.00 | 34.00 | 31.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 31.00 | 31.00 | 30.00 | 30.00 | 30.00 | 44.00 | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 2,386 | 2,542 | 2,549 | 2,562 | 2,592 | 2,607 | 2,622 | 2,673 | 2,680 | 2,688 | 2,720 | 2,728 | 2,735 | 2,757 | 2,765 | 2,772 | 2,609 | 2,614 | 2,620 | 2,625 |
Shareholder's Equity | -421.7% | -63.63 | 20.00 | 331 | 151 | 135 | 298 | 194 | 173 | 407 | 367 | 383 | 390 | 367 | 345 | 348 | 371 | 403 | 347 | 396 | 749 | 800 |
Retained Earnings | -18.7% | -581 | -490 | -391 | -401 | -413 | -406 | -401 | -399 | -278 | -276 | -269 | -265 | -280 | -286 | -283 | -274 | -262 | -377 | -345 | -80.75 | -63.84 |
Additional Paid-In Capital | -0.1% | 539 | 539 | 715 | 708 | 701 | 692 | 684 | 676 | 667 | 658 | 651 | 643 | 634 | 628 | 623 | 618 | 612 | 607 | 566 | 544 | 537 |
Shares Outstanding | 74.5% | 307 | 176 | 153 | 153 | 152 | 151 | 151 | 151 | 150 | 149 | 149 | 149 | 148 | 147 | 148 | 147 | 147 | 132 | 129 | 128 | 128 |
Minority Interest | -58.7% | 0.00 | 0.00 | -176 | -167 | -159 | -114 | -103 | -107 | 16.00 | 7.00 | 33.00 | 44.00 | 44.00 | 42.00 | 47.00 | 65.00 | 85.00 | 115 | 178 | 290 | 328 |
Float | - | - | - | - | 464 | - | - | - | 471 | - | - | - | 751 | - | - | - | 696 | - | - | - | 1,202 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -103.2% | -4.41 | 136 | 81.00 | -11.34 | 140 | -23.29 | 94.00 | -125 | 120 | 63.00 | 82.00 | -51.93 | 148 | 106 | 45.00 | 179 | 49.00 | -50.89 | 140 | 21.00 | -108 |
Share Based Compensation | 12.5% | 7.00 | 6.00 | 7.00 | 7.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 5.00 | 5.00 | 5.00 | 6.00 | 5.00 | 5.00 | 6.00 | 6.00 | 4.00 |
Cashflow From Investing | 37.6% | -19.76 | -31.69 | -13.48 | -12.28 | -11.74 | -11.47 | -49.33 | -16.12 | -97.39 | -86.97 | -11.63 | -82.89 | -12.69 | -31.79 | -14.78 | -8.93 | -262 | -4.77 | 30.00 | -23.33 | -21.47 |
Cashflow From Financing | 77.0% | -23.15 | -100 | -86.58 | -12.26 | -12.90 | -22.17 | -46.13 | 23.00 | -61.57 | -30.35 | -43.55 | -38.07 | -26.15 | -11.28 | -14.81 | -310 | 468 | -7.30 | -7.60 | -9.07 | -21.86 |
Dividend Payments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Net revenue | $ 659,191 | $ 557,540 |
Cost of goods sold | 421,131 | 379,354 |
Gross profit | 238,060 | 178,186 |
Selling, general and administrative | 112,595 | 102,096 |
Research and development | 39,298 | 38,690 |
Intellectual property legal development expenses | 984 | 1,644 |
Restructuring and other charges | 1,470 | 510 |
Change in fair value of contingent consideration | 100 | 2,457 |
Charges (credit) related to legal matters, net | 94,359 | (436) |
Other operating income | 0 | (1,224) |
Operating (loss) income | (10,746) | 34,449 |
Other (expense) income: | ||
Interest expense, net | (65,703) | (49,315) |
Foreign exchange (loss) gain, net | (1,197) | 1,901 |
Increase in tax receivable agreement liability | (1,948) | (826) |
Other income, net | 4,072 | 4,365 |
Total other expense, net | (64,776) | (43,875) |
Loss before income taxes | (75,522) | (9,426) |
Provision for income taxes | 6,156 | 668 |
Net loss | (81,678) | (10,094) |
Less: Net (income) loss attributable to non-controlling interests | (9,965) | 3,151 |
Net loss attributable to Amneal Pharmaceuticals, Inc. | $ (91,643) | $ (6,943) |
Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders: | ||
Basic (in dollars per share) | $ (0.30) | $ (0.05) |
Diluted (in dollars per share) | $ (0.30) | $ (0.05) |
Weighted-average common shares outstanding: | ||
Basic (in shares) | 307,279 | 152,109 |
Diluted (in shares) | 307,279 | 152,109 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 46,520 | $ 91,542 |
Restricted cash | 5,097 | 7,565 |
Inventories | 570,653 | 581,384 |
Prepaid expenses and other current assets | 87,298 | 82,685 |
Total current assets | 1,380,044 | 1,377,863 |
Property, plant and equipment, net | 439,815 | 447,574 |
Goodwill | 598,549 | 598,629 |
Intangible assets, net | 859,272 | 890,423 |
Other assets | 73,747 | 55,517 |
Total assets | 3,456,397 | 3,472,569 |
Current liabilities: | ||
Current portion of liabilities for legal matters | 30,130 | 76,988 |
Revolving credit facility | 179,000 | 179,000 |
Current portion of long-term debt, net | 33,660 | 34,125 |
Total current liabilities | 834,388 | 846,595 |
Long-term debt, net | 2,377,707 | 2,386,004 |
Note payable - related party | 41,893 | 41,447 |
Liabilities for legal matters - long term | 85,479 | 316 |
Total long-term liabilities | 2,638,616 | 2,564,670 |
Commitments and contingencies (Notes 4 and 17) | ||
Redeemable non-controlling interests | 47,022 | 41,293 |
Stockholders' (Deficiency) Equity | ||
Preferred stock, $0.01 par value, 2,000 shares authorized at both March 31, 2024 and December 31, 2023; none issued at both March 31, 2024 and December 31, 2023 | 0 | 0 |
Additional paid-in capital | 538,720 | 539,240 |
Stockholders' accumulated deficit | (581,819) | (490,176) |
Accumulated other comprehensive loss | (23,711) | (32,349) |
Total Amneal Pharmaceuticals, Inc. stockholders' (deficiency) equity | (63,724) | 19,781 |
Non-controlling interests | 95 | 230 |
Total stockholders' (deficiency) equity | (63,629) | 20,011 |
Total liabilities and stockholders' (deficiency) equity | 3,456,397 | 3,472,569 |
Related Party | ||
Current assets: | ||
Trade accounts receivable, net | 1,521 | 955 |
Operating lease right-of-use assets | 12,468 | 12,954 |
Current liabilities: | ||
Accounts payable and accrued expenses | 17,075 | 7,321 |
Current portion of operating lease liabilities - related party | 3,192 | 2,825 |
Operating lease liabilities | 11,969 | 12,787 |
Other long-term liabilities | 11,394 | 11,776 |
Nonrelated Party | ||
Current assets: | ||
Trade accounts receivable, net | 668,955 | 613,732 |
Operating lease right-of-use assets | 32,970 | 30,329 |
Financing lease right-of-use assets | 59,532 | 59,280 |
Current liabilities: | ||
Accounts payable and accrued expenses | 558,518 | 534,662 |
Current portion of operating lease liabilities | 9,508 | 9,207 |
Current portion of financing lease liabilities | 3,305 | 2,467 |
Operating lease liabilities | 26,786 | 24,095 |
Financing lease liabilities | 58,809 | 58,566 |
Other long-term liabilities | 24,579 | 29,679 |
Common Class A | ||
Stockholders' (Deficiency) Equity | ||
Common stock | 3,086 | 3,066 |
Common Class B | ||
Stockholders' (Deficiency) Equity | ||
Common stock | $ 0 | $ 0 |
 | Mr. Chirag K. Patel |
---|---|
 | https://amneal.com |
 | Pharmaceuticals |
 | 7600 |